Profile | GDS2987 / GI_27477093-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 6.8 | 25 |
GSM215244 | HMVEC_vehicle_rep2 | 22.3 | 49 |
GSM215253 | HMVEC_vehicle_rep3 | 11.2 | 36 |
GSM215254 | HMVEC_atorvastatin_rep1 | 52.6 | 69 |
GSM215282 | HMVEC_atorvastatin_rep3 | 27.8 | 53 |
GSM215344 | HMVEC_atorvastatin_rep2 | 33.4 | 60 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 12 | 24 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 13.4 | 22 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 20.9 | 39 |
GSM215296 | HMVEC_SLx2119_rep3 | 57.8 | 65 |
GSM215297 | PASMC_vehicle_rep1 | 32.2 | 45 |
GSM215298 | PASMC_vehicle_rep2 | 40.7 | 53 |
GSM215310 | PASMC_vehicle_rep3 | 4.6 | 8 |
GSM215311 | PASMC_atorvastatin_rep1 | 32.8 | 50 |
GSM215312 | PASMC_atorvastatin_rep2 | 11.6 | 19 |
GSM215313 | PASMC_atorvastatin_rep3 | 27.8 | 39 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 8.3 | 14 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 49.9 | 64 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 35.4 | 52 |
GSM215327 | PASMC_SLx2119_rep1 | 21.4 | 36 |
GSM215328 | PASMC_SLx2119_rep2 | 35.2 | 53 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 19.8 | 42 |
GSM215331 | Fibroblasts_vehicle_rep2 | 19.5 | 47 |
GSM215332 | Fibroblasts_vehicle_rep3 | 15 | 44 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 2.2 | 6 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 12.5 | 34 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 33.2 | 59 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 25.4 | 59 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 18.6 | 50 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 40.8 | 66 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 34.7 | 64 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 32 | 61 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 31.4 | 59 |